Emergent BioSolutions
NYSE/NASDAQ:EBSBiotechGaithersburg, Maryland, United States · Est. 1998 · 2,400 employees
Emergent BioSolutions is a speciality biopharmaceutical company focused on vaccines, specialty immunoglobulin products, and contract manufacturing services for the U.S. government and commercial customers.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
44
Clinical Trials↗
All sponsored trials (all statuses)
5
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Recent Activity
Last 14 days
Sep 14, 2026
8-K
8-K
Earlier
Sep 1, 20268-K8-K
Aug 20, 2026TrialA Phase 1, Open Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adult Participants
Aug 5, 20268-K8-K
Jun 29, 20268-K8-K
Mar 3, 20268-KEmergent BioSolutions Inc. (EBS) (CIK 0001367644)
May 30, 2023TrialStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
Dec 21, 2021TrialStudy of SIAN Nasal Spray in Healthy Adults
Details
Company Info
Company Overview
$2.1B
Mkt Cap
$1.0B
Revenue
$111.7M
Cash
CEORobert G. Kramer
Founded1998
Employees2,400
HQGaithersburg, Maryland, United States
ExchangeNYSE/NASDAQ:EBS
Websiteemergentbiosolutions.com
LinkedInCompany Page
Therapeutic Focus
NeurologyInfectious DiseaseRespiratoryImmunologyOtherOncology
Recent SEC Filings
8-KSep 14, 2026
8-K
8-KSep 1, 2026
8-K
8-KAug 5, 2026
8-K
8-KJun 29, 2026
8-K
8-KMar 3, 2026
Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Regulatory
Regulatory Timeline
20121 event
FDADec 14
RAXIBACUMAB — RAXIBACUMAB
Application BLA125349 (BLA)
20201 event
FDADec 21
EBANGA — EBANGA
Application BLA761172 (BLA)
20212 events
FDAJun 4
Tembexa — TEMBEXA
Application NDA214460 (NDA)
FDAJun 4
Tembexa — TEMBEXA
Application NDA214461 (NDA)
20265 events
SECSep 14
8-K
Accession: 0001367644-26-000091
SECSep 1
8-K
Accession: 0001367644-26-000088
SECAug 5
8-K
Accession: 0001367644-26-000080
SECJun 29
8-K
Accession: 0001367644-26-000068
SECMar 3
Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Accession: 001-33137
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)